Neurology | Phase III Developments | JAPAN

Chugai Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder

Lead Product(s): Satralizumab

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2020

Details:

Satralizumab monotherapy significantly reduced risk of relapse in patients with NMOSD, following a previous positive study where satralizumab was added to baseline immunosuppressant therapy.

Chugai Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Chugai’s Huntington's disease drug, RG6042 gets Japanese orphan drug designation

Lead Product(s): Onis-Httrx

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2020

Details:

The company is running a clinical study in cooperation with Roche to deliver RG6042 to patients with Huntington's disease, as the first disease-modifying drug.

Kissei Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneratio...

Lead Product(s): Rovatirelin

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

In this paper, to review the results of both phase III clinical trials, a pooled (post hoc) analysis was performed with patients who met the inclusion criteria for the additional phase III trial

Find

Find Neurology Drugs in Phase III Clinical Development in JAPAN

Japan

A collaboration with SCORR Marketing

Product Type

Companies

Chugai Pharmaceutical

Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder

Chugai Pharmaceutical

Chugai’s Huntington's disease drug, RG6042 gets Japanese orphan drug designation

Kissei Pharmaceutical

Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneratio...